Brief: Glenmark Pharma Says US FDA Completes Inspection At Aurangabad Facility
01/12/2025 04:12
Dec 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA - U.S. FDA COMPLETES INSPECTION AT GLENMARK'S AURANGABAD FACILITY GLENMARK PHARMA - INSPECTION CONCLUDED WITH ZERO 483 OBSERVATIONS Source text: ID:nNSE5GC4Wj Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter